Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q2 FY26 results · Jul–Sep 2025

Jubilant Pharmova reported revenue from operations of ₹1,966.40 crore (up 12.2% from Q2 FY25) and net profit of ₹119.90 crore (up 17.0% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	1,966.40	1,752.30	+12.2%	1,900.70	+3.5%
Other income	9.80	21.70	−54.8%	12.00	−18.3%
Total income	1,976.20	1,774.00	+11.4%	1,912.70	+3.3%
Profit before share of associates & JVs and tax	190.40	144.50	+31.8%	154.50	+23.2%
Share of profit/(loss) of associates & JVs	(0.10)	(0.10)		(0.10)
Net profit for the period	119.90	102.50	+17.0%	102.50	+17.0%
Attributable to shareholders of the company	120.30	102.80	+17.0%	102.90	+16.9%
EPS, basic (₹)	7.59	6.47	+17.3%	6.49	+16.9%
Net margin (%)	6.1	5.8		5.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	66.40	165.70	−59.9%	59.50	+11.6%
Other income	0.80	43.80	−98.2%	0.70	+14.3%
Total income	67.20	209.50	−67.9%	60.20	+11.6%
Profit before tax	8.50	16.60	−48.8%	6.50	+30.8%
Net profit for the period	(6.40)	10.50	Turned loss	5.80	Turned loss
EPS, basic (₹)	(0.40)	0.66	Turned loss	0.36	Turned loss
Net margin (%)	-9.6	6.3		9.7

Consolidated

Filed with BSE: 31 Oct 2025, 18:33 IST
Board meeting: 31 Oct 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 31 Oct 2025, 18:33 IST
Board meeting: 31 Oct 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE